(Q48031815)

7 February 2018

title

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. (English)

1 reference

7 February 2018

1 reference

6

Hans-Peter Hartung

1 reference

7 February 2018

9

Ludwig Kappos

1 reference

7 February 2018

16

Frederik Barkhof

1 reference

7 February 2018

7

David Miller

1 reference

7 February 2018

author name string

Gijsbert J A Nagtegaal

1

1 reference

7 February 2018

Christoph Pohl

2

1 reference

7 February 2018

Mike P Wattjes

3

1 reference

7 February 2018

Hanneke E Hulst

4

1 reference

7 February 2018

Mark S Freedman

5

1 reference

7 February 2018

Xavier Montalban

8

1 reference

7 February 2018

Gilles Edan

10

1 reference

7 February 2018

Dirk Pleimes

11

1 reference

7 February 2018

Karola Beckman

12

1 reference

7 February 2018

Brigitte Stemper

13

1 reference

7 February 2018

Christoph H Polman

14

1 reference

7 February 2018

Rupert Sandbrink

15

1 reference

7 February 2018

publication date

10 July 2013

1 reference

7 February 2018

Multiple Sclerosis Journal

published in

1 reference

7 February 2018

volume

20

1 reference

7 February 2018

issue

2

1 reference

7 February 2018

page(s)

234-242

1 reference

7 February 2018

https://api.crossref.org/works/10.1177%2F1352458513494491

uses

randomized experiment

0 references

1 reference

Clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Black holes in multiple sclerosis: definition, evolution, and clinical correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

The limits of functional reorganization in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513494491

21 January 2018

Identifiers

DOI

10.1177/1352458513494491

1 reference

7 February 2018

PubMed ID

23842212

1 reference

7 February 2018